ANV221

About Anviron

Anviron is an emerging oncology biotech leveraging a glycome-focused platform to develop inhibitors of glycosyltransferases, key enzymes in cancer signaling. Its pipeline is anchored by ANV221, which has demonstrated strong preclinical results in pancreatic ductal adenocarcinoma and drug-resistant HER2+ breast cancer models, leading to orphan drug designation for pancreatic cancer. The company, founded in 2020 (contradicting earlier data), has built a robust intellectual property portfolio with patents granted in the US, Europe, and Japan, and is supported by academic collaborations and a seasoned advisory board. Anviron is currently in the preclinical/IND-enabling stage, seeking investment to advance its lead programs toward clinical trials.

About Anviron

Anviron is an emerging oncology biotech leveraging a glycome-focused platform to develop inhibitors of glycosyltransferases, key enzymes in cancer signaling. Its pipeline is anchored by ANV221, which has demonstrated strong preclinical results in pancreatic ductal adenocarcinoma and drug-resistant HER2+ breast cancer models, leading to orphan drug designation for pancreatic cancer. The company, founded in 2020 (contradicting earlier data), has built a robust intellectual property portfolio with patents granted in the US, Europe, and Japan, and is supported by academic collaborations and a seasoned advisory board. Anviron is currently in the preclinical/IND-enabling stage, seeking investment to advance its lead programs toward clinical trials.

Therapeutic Areas

Other Pancreatic Ductal Adenocarcinoma Drugs